| 董晶,王邦才,施航.复方土贝母制剂联合化疗治疗晚期三阴性乳腺癌临床观察[J].浙江中西医结合杂志,2019,29(3): |
| 复方土贝母制剂联合化疗治疗晚期三阴性乳腺癌临床观察 |
| Clinical observation of compound Tubeimu preparation(复发土贝母制剂） combined with chemotherapy in the treatment of advanced triple-negative breast cancer |
| 投稿时间：2018-07-29 修订日期：2019-01-14 |
| DOI： |
| 中文关键词: 晚期三阴性乳腺癌 复方土贝母制剂 化疗 增效 |
| 英文关键词:Late triple-negative breast cancer Compound Tubeimu preparation chemotherapy synergy |
| 基金项目:宁波市自然科学基金项目(NO.2017A610167),浙江省名老中医专家传承工作室王邦才工作室(NO.GZS2017017),国家中医药管理局“十二五”重点专科建设项目(国中医药医政发[2012]2号) |
|
| 摘要点击次数: 873 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的：评价复方土贝母制剂联合化疗治疗晚期三阴性乳腺癌疗效。方法： 将2013年1月至2016年12月宁波市中医院肿瘤科收治的70例晚期三阴性乳腺癌患者随机分为治疗组与对照组各35例,对照组予化疗,治疗组在化疗同时予口服复方土贝母制剂,观察近期临床疗效、治疗前后中医症状积分、生存质量(KPS)评分、无进展生存期(PFS)。结果：两组近期有效率分别为65.7%和42.8%,差异有统计学意义(P<0.05)；治疗组治疗后各项中医症状积分较治疗前降低(P<0.05),治疗后治疗组各项中医症状积分均低于对照组(P<0.05),两组生活质量改善率分别为62.9%和45.7%,差异有统计学意义(P<0.05)。两组中位无进展生存期(PFS)分别为8.4个月和5.6个月,差异有统计学意义(P<0.05)。结论：复方土贝母制剂可提高化疗疗效,改善患者临床症状和生存质量,延长无进展生存期。 |
| 英文摘要: |
| Objective：To evaluate the efficacy of compound Tubeimu preparation combined with chemotherapy in the treatment of advanced triple-negative breast cancer. METHODS: From January 2013 to December 2016, 70 patients with advanced triple-negative breast cancer admitted to the Department of Oncology of Ningbo Hospital of Traditional Chinese Medicine were randomly divided into treatment group and control group, 35 cases in each group. The control group received chemotherapy. The treatment group was based on chemotherapy. Oral compound Tubeimu preparations were administered to observe the clinical efficacy, TCM symptom scores before and after treatment, quality of life (KPS) score, and progression-free survival (PFS). Results: The recent effective rates of the two groups were 65.7% and 42.8%, respectively, and the difference was statistically significant (P<0.05). The scores of TCM symptoms in the treatment group were lower than those before treatment (P<0.05). The scores of TCM symptoms were lower than those of the control group (P<0.05). The improvement rate of quality of life in the two groups was 62.9% and 45.7%, respectively, and the difference was statistically significant (P<0.05). The median progression-free survival (PFS) was 8.4 months and 5.6 months, respectively, and the difference was statistically significant (P<0.05). Conclusion: Compound Tubeimu can improve the efficacy of chemotherapy, improve the clinical symptoms and quality of life, and prolong progression-free survival of patients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
